Praxis Precision Medicines has scored another midphase win in epilepsy this year, with its sodium channel inhibitor shown to reduce seizures in children with two specific types of the neurological disorder.
Recursion has stumbled through an early test of its tech-enabled approach to drug discovery, reporting a hit on its phase 2 primary endpoint of safety and tolerability but failing to wow on the efficacy front.
Call it a case of good chemistry: Acepodia, a biotech based on Nobel Prize-winning science, is entering into a new partnership with Pfizer’s Ignite program to support development of the biotech’s unique cell immunotherapies.
France-based clinical research company Aixial Group is consolidating clinical data from one of its business units into Medidata’s digital platform, according to a Sept. 3 release.
After escaping a clinical hold several years back, Dyne Therapeutics has revealed new phase 1/2 data for its Duchenne muscular dystrophy (DMD) therapy DYNE-251. The readout notes several serious treatment-emergent adverse events (TEAEs), including acute kidney injury.
America’s job market rebounded in November, adding 227,000 workers in a solid recovery from the previous month, when the effects of strikes and hurricanes had sharply diminished employers’ payrolls
U.S. stocks rose to records after data suggested the job market remains solid enough to keep the economy going, but not so strong that it raises immediate worries about inflation
BofA says visit to Giga Texas confirms that FSD progress supports a 2025 robotaxi launch, and Optimus is ‘real’
There are signs that demand for cruises keep growing, with record bookings post-Thanksgiving
ProKidney has stopped one of a pair of phase 3 trials for its cell therapy for kidney disease after deciding it wasn’t essential for securing FDA approval.
Edgewise’s stock jumps 50% on the back of safety data for potential heart disease rival to Camzyos
In 2 papers, researchers describe potential new neurodegenerative disease treatment approach
Aligos’ MASH prospect slashes liver fat in phase 2, but stock drops anyway
Vanda receives FDA rejection, issues fiery response against ‘conclusory’ refusal
Jury rules for Axonics in Medtronic’s long-running neuromodulation patent lawsuit
Achilles drops cell therapy program, braces for layoffs after missing ‘commercial viability’ goals
Basilea scores $268M BARDA funding deal to work on antifungals, antibiotics
From ‘science fiction to reality’: New George Church-founded biotech raises $75M for cell therapy platform
How the Stock Market Defied Expectations Again This Year, by the Numbers
US Applications for Unemployment Benefits Hold Steady, but Continuing Claims Rise to 3-Year High
